MajorCentrally acting psychostimulant×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Methylphenidate raises extracellular dopamine, while pimozide is an antipsychotic. The Spanish methylphenidate summary of product characteristics (SmPC) warns of possible pharmacodynamic interactions with dopamine antagonists, including antipsychotics (methylphenidate SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents describe no pharmacokinetic interaction for the pair. Cytochrome P450 enzymes do not metabolise methylphenidate to a clinically relevant degree, and methylphenidate does not markedly inhibit CYP3A4 or CYP2D6, the enzymes that clear pimozide (methylphenidate and pimozide SmPCs, AEMPS). The restriction in the US pimozide label concerns diagnosis. Methylphenidate can itself cause motor and vocal tics, and in the US pimozide is used only to suppress tics in Tourette's syndrome (pimozide and methylphenidate labels, US Food and Drug Administration, FDA).
Symptoms
Methylphenidate can cause or worsen motor and vocal tics, and worsening of Tourette's syndrome has been reported (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and label, US Food and Drug Administration, FDA). Tics in a person taking methylphenidate may therefore be caused by the drug itself (pimozide FDA label). In people with psychosis, methylphenidate can worsen behaviour and thought disorders, and in people with no history of psychosis it can cause hallucinations, delusions or mania (methylphenidate SmPC, AEMPS). Among antipsychotics, the US methylphenidate label names only risperidone: a change in the dose of either drug may increase the risk of extrapyramidal symptoms. The documents give no such warning for pimozide (methylphenidate FDA label).
Management
The US pimozide label contraindicates pimozide in people taking methylphenidate or other drugs that can cause tics. The ban lasts until these drugs are stopped and it becomes clear whether the drug or Tourette's syndrome causes the tics (pimozide label, US Food and Drug Administration, FDA). The ban concerns the diagnosis of tics. In the US, pimozide is indicated only for Tourette's syndrome and is contraindicated for simple tics and tics of other origin (pimozide FDA label). In Spain, pimozide is authorised for acute and chronic psychoses and anxiety disorders, and tics are not among its indications. The Spanish pimozide summary of product characteristics (SmPC) does not mention methylphenidate (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish methylphenidate SmPC advises caution with antipsychotics. Methylphenidate is contraindicated in people with current or past psychotic symptoms or schizophrenia, regardless of pimozide (methylphenidate SmPC, AEMPS). Before starting methylphenidate, assess the person and the family history for tics and Tourette's syndrome. During treatment, monitor for new or worsening tics at every dose change and at least every 6 months (methylphenidate SmPC, AEMPS). If psychotic symptoms appear, consider whether methylphenidate caused them. Stopping methylphenidate may be appropriate (methylphenidate SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and repeat it during treatment. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Metilfenidato (nº registro 65148), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65148 (Concerta 18 mg, Janssen), revisión 03/2026, secciones 4.4, 4.5 y 5.1
- FDA: CONCERTA (methylphenidate hydrochloride) prescribing information (2026)– FDA, DailyMed setid 1a88218c-5b18-4220-8f56-526de1a276cd (Janssen), revisión 04/2026 (versión 30), secciones 4, 5.3 y 7